High efficiency CRISPR knock-in demonstrates that TCF1 is insufficient to reverse T cell exhaustion.

Saved in:
Bibliographic Details
Title: High efficiency CRISPR knock-in demonstrates that TCF1 is insufficient to reverse T cell exhaustion.
Authors: de Menezes MN; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, 3000, Victoria, Australia. maria.nogueirademenezes@petermac.org.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, 3010, Australia. maria.nogueirademenezes@petermac.org., Chen AXY; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, 3000, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, 3010, Australia., Kulkarni N; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, 3000, Victoria, Australia., Sampurno S; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, 3000, Victoria, Australia., Saw NYL; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, 3000, Victoria, Australia., Yap KM; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, 3000, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, 3010, Australia., Pérez-Núñez I; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, 3000, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, 3010, Australia., Roth S; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, 3000, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, 3010, Australia., Deguit CDT; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, 3000, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, 3010, Australia., Haugen B; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, 3000, Victoria, Australia., Ramsbottom KM; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, 3000, Victoria, Australia., Munoz I; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, 3000, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, 3010, Australia., Beavis PA; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, 3000, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, 3010, Australia., Parish IA; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, 3000, Victoria, Australia. ian.parish@petermac.org.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, 3010, Australia. ian.parish@petermac.org.
Source: Nature communications [Nat Commun] 2026 Feb 17; Vol. 17 (1). Date of Electronic Publication: 2026 Feb 17.
Publication Type: Journal Article
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2041-1723
DOI:10.1038/s41467-026-69671-y